Panelists discuss how treatment selection is personalized based on patient characteristics, with relatlimab-nivolumab or monotherapy preferred for frail patients with low disease burden, while ipilimumab-nivolumab might be considered for patients with brain metastases despite its higher toxicity.
Of Interest
Navigating Newer Treatment Regimens in Melanoma: Practical Approaches to Dosing and Adverse Event Management
Community adoption of newer immunotherapy combinations.
Dr Luke on the Role of IMA203 in Previously Treated Advanced Cutaneous Melanoma
Jason Luke, MD, associate director for clinical research and director of the Immunotherapy and Drug Development Center at Hillman Cancer Center, University of Pittsburgh, discussed the design and potential clinical effects of the phase 3 SUPRAME trial (NCT06743126), which is evaluating the efficacy of IMA203, a T-cell receptor–transduced T-cell therapy (TCR-T), vs investigator’s choice of standard therapy in patients with previously treated advanced cutaneous melanoma.
Making Sense of Melanoma Adjuvant Treatment in the Absence of OS Data
We will finalize this series on where we should go, and what’s next in terms of immunotherapy in the adjuvant setting, by looking into the two other aspects that we need to consider when we discuss the factthat there is no overall survival benefit nor are there data on the overall survival benefit for patients treated with immunotherapy in the adjuvant setting.